XM does not provide services to residents of the United States of America.
A
A

Agilent

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

U.S. earnings week ahead

DIARY-U.S. earnings week ahead May 24 (Reuters) - Diary of U.S. (.SPX) corporate earnings for the week ahead. ** Please Note - All times given are in U.S. EDT unless otherwise stated ** U.S. EARNINGS Start Date Start Time RIC Company Name Event Name 29-May-2024 AMC A Agilent Technologies Inc Q2 2024 Agilent Technologies Inc Earnings Release 29-May-2024 AMC CRM Salesforce Inc Q1 2025 Salesforce Inc Earnings Release 29-May-2024 AMC HPQ HP Inc Q2 2024 HP Inc Earnings Release 30-May-2024 16:15 COO.O
A
C
N
S
U

Masimo prepared to provide one board seat if activist Politan drops proxy contest

UPDATE 4-Masimo prepared to provide one board seat if activist Politan drops proxy contest Adds Politan's response in paragraph 4, 6, 8 and 9 By Christy Santhosh and Pratik Jain May 9 (Reuters) - Masimo MASI.O said on Thursday that it is prepared to appoint Politan Capital Management's nominee William Jellison as a director on its board, if the activist investor withdraws its other nominee and drops its proxy contest.
A
S

Padraig Mcdonnell Assumes Agilent CEO Role

BRIEF-Padraig Mcdonnell Assumes Agilent CEO Role May 1 (Reuters) - Agilent Technologies Inc A.N : PADRAIG MCDONNELL ASSUMES AGILENT CEO ROLE Source text for Eikon: ID:nBwdLXbPa Further company coverage: A.N
A

U.S. Blackline, Medpace Holdings, Roblox

U.S. RESEARCH ROUNDUP-Blackline, Medpace Holdings, Roblox April 23 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Blackline, Medpace Holdings and Roblox on Tuesday. HIGHLIGHTS * Airbnb Inc ABNB.O : Jefferies raises target price to $150 from $145 * Blackline Inc BL.O : Piper Sandler raises to neutral from underweight * Intel INTC.O : HSBC cuts PT to $37 from $44 * Medpace Holdings Inc MEDP.O : Jefferies raises to buy
A
A
A
C
E
I
K
V
Z
L
B
A
A
C

U.S. 3M, J&J, Nuvalent

U.S. RESEARCH ROUNDUP-3M, J&J, Nuvalent April 17 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including 3M, J&J and Nuvalent, on Wednesday. HIGHLIGHTS * 3M Co MMM.N : JP Morgan cuts target price to $110 from $118 * J&J JNJ.N : RBC cuts target price to $175 from $181 * Nuvalent Inc NUVL.O : Jefferies initiates coverage with buy rating; price target $97 * Tractor Supply Co TSCO.O : Barclays raises target price to $234 from $1
A
A
A
B
B
C
G
J
I
A
C
F

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.